{"id":30,"date":"2025-07-30T11:00:42","date_gmt":"2025-07-30T11:00:42","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=30"},"modified":"2025-09-07T13:19:13","modified_gmt":"2025-09-07T13:19:13","slug":"china-bd-deal-gsk-and-hengrui","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/30.html","title":{"rendered":"[China BD 2025] Hengrui and GSK \u00a0achieved a 12.5 billion USD license on PDE3\/4 inhibitor HRS-9821 and 11 other assets"},"content":{"rendered":"\n

Announced Date: 2025-07-28 (JULY 28, 2025)<\/p>\n\n\n\n

Asset Name: HRS-9821 and other 11 preclinical medicines<\/p>\n\n\n\n

Licensor: Hengrui Pharma (600276.SH; 01276.HK) (Headquarter Shanghai City, China)<\/p>\n\n\n\n

Licensee (Buyer): GSK plc<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Asset Target: PDE3\/4 inhibitor(HRS-9821), etc<\/p>\n\n\n\n

Asset Modality: Small Molecule, or other<\/p>\n\n\n\n

Current Stage:HRS-9821 in Phase I, other 11 asset all in preclinical ;<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Scope of Authority:<\/p>\n\n\n\n

GSK will exclusive worldwide license (excluding mainland China, Hong Kong, Macau and Taiwan) for PDE3\/4 inhibitor (HRS-9821) ; <\/p>\n\n\n\n

GSK will have the exclusive option to further develop and commercialise each programme (up to 11 programmes) worldwide (excluding mainland China, Hong Kong, Macau and Taiwan), at the end of phase I or earlier at GSK\u2019s election, as well as certain programme substitution rights. <\/p>\n\n\n\n

.<\/p>\n\n\n\n

Deal Detail:<\/p>\n\n\n\n

Upfront payment of $500 million<\/p>\n\n\n\n

Milestone payments up to  approximately $12 billion<\/p>\n\n\n\n

Royalties on net sales,  tiered<\/p>\n\n\n\n

Total 12.5 billion plus<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Link:<\/p>\n\n\n\n

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology<\/p>\n\n\n\n

https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-and-hengrui-pharma-enter-agreements\/<\/a> <\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Announced Date: 2025-07-28 (JULY 28, 2025) Asset Name: HRS-9821 and other 11 preclinical medicines Licensor: Hengrui … [China BD 2025] Hengrui and GSK \u00a0achieved a 12.5 billion USD license on PDE3\/4 inhibitor HRS-9821 and 11 other assets<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-30","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/30","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=30"}],"version-history":[{"count":5,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/30\/revisions"}],"predecessor-version":[{"id":240,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/30\/revisions\/240"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=30"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=30"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}